查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1454244

全球抗生素抗药性市场：按药物类别、疾病、分销管道和地区分类

Global Antibiotic Resistance Market, By Drug Class, By Disease (cUTI, CDI, ABSSSI, HABP, CABP, cIAI, Others (BSI, etc.)), By Distribution Channel, By Geography .
出版日期: | 出版商: Coherent Market Insights | 英文 180 Pages | 商品交期: 2-3个工作天内

价格
简介目录

预计2023年全球抗生素抗药性市场价值为88.3亿美元，预计2031年将达133.7亿美元，2024年至2031年复合年增长率为5.3%。

报告范围 报告详情
基准年 2023年 2023/2024年市场规模 88.3亿美元
实际资料 2019-2023 预测期 2024-2031
预测期间 2023/2024 至 2030/2031 年复合年增长率： 5.30% 2030/2031价值预测 133.7亿美元
图 1. 2023 年全球抗生素抗药性市场占有率(%)（按地区）
全球抗生素抗药性市场-IMG1

近年来，全球抗生素抗药性市场经历了显着增长。抗生素是用于预防和治疗细菌感染的药物。抗生素要么杀死细菌，要么阻止它们生长。最常使用的抗生素包括青霉素、阿莫西林和头孢菌素。然而，在过去的几十年里，抗生素抗药性已成为全球公共卫生的主要威胁。当细菌对抗生素产生抗药性时，用于治疗细菌引起的感染疾病的药物就会失效。结果，疾病时间延长，死亡率增加。对各种抗生素具有抗药性的细菌菌株数量不断增加，主要是由于抗生素的滥用和过度使用。促进抗生素抗药性的其他因素包括缺乏新抗生素的开发、世界许多地区缺乏卫生设施以及国际旅行的增加。如果处理不当，抗生素抗药性可能会导致严重的健康问题并影响患者的治疗结果。

市场动态：

全球抗生素抗药性市场的成长是由抗生素抗药性细菌感染疾病日益流行、新抗生素缺乏市场开拓、现有抗生素滥用和过度使用以及许多新兴市场的感染控制有限所推动的。等因素。然而，替代治疗方法的发展和有关抗生素使用的严格规定可能会抑制市场成长。该市场为专注于开拓具有新作用机制的新型抗生素的公司提供了机会。主要企业也在探索替代治疗方法，例如噬菌体疗法、疫苗和单株抗体，以对抗抗生素抗药性。工业界和学术界之间的合作是解决这一迫在眉睫的医疗保健危机的一个有希望的途径。

本研究的主要特点

  • 本报告详细分析了全球抗生素抗药性市场，并提供了以2023年为基准年的预测期（2024-2031）的市场规模和年复合成长率（CAGR%）。
  • 它还说明了各个细分市场的潜在收益成长机会，并为该市场提供了一系列有吸引力的投资提案。
  • 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
  • 它根据公司亮点、产品系列、主要亮点、财务表现和策略等参数，介绍了全球抗生素抗药性市场的主要企业。
  • 该报告的见解使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
  • 全球抗生素抗药性市场报告迎合了该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
  • 相关人员可以透过用于分析全球抗生素抗药性市场的各种策略矩阵来促进他们的决策。

目录

第一章 研究目的与前提

  • 研究目标
  • 先决条件
  • 简称

第二章 市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第三章市场动态、法规及趋势分析

  • 市场动态
    • 感染疾病的传播
    • 抗生素抗药性诊断的进展
    • 增加研发活动
  • 主要亮点
  • 临时劳务派遣机构和公司指南
  • 市场趋势
  • PEST分析
  • 投资金筹措
  • 合併、收购和合作
  • 主要提供服务
  • 识别顶级市场参与者
  • 护士安置的优势
  • 按国家/地区分類的医疗保健支出

第四章全球抗生素抗药性市场－冠状病毒（COVID-19）大流行的影响

  • 新型冠状病毒感染疾病（COVID-19）的流行病学
  • 供需面分析
  • 经济影响

第五章全球抗生素抗药性市场，依药物类别，2019-2031

  • Oxazolidinone
  • 胜肽
  • 四环霉素
  • 头孢菌素类
  • 其他（联合治疗等）

第六章 全球抗生素抗药性市场，依疾病分类，2019-2031

  • cUTI（复杂性尿道感染）
  • CDI（困难梭状桿菌感染疾病）
  • ABSSSI（急性细菌性皮肤和皮肤结构感染疾病）
  • HABP（医院细菌性肺炎）
  • CABP（社区型肺炎）
  • cIAI（复杂性腹腔内感染疾病）
  • 其他（BSI（血流感染疾病）等）

第七章全球抗生素抗药性市场，依通路，2019-2031

  • 医院药房
  • 零售药房
  • 网路药房

第八章全球抗生素抗药性市场（按地区），2019-2031

  • 北美洲
  • 美国
  • 加拿大
  • 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 欧洲其他地区
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • ASEAN
  • 其他亚太地区
  • 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东地区
  • 非洲
  • 北非
  • 中部非洲
  • 南非

第9章 竞争格局

  • 公司简介
    • Melinta Therapeutics
    • Merck &Co., Inc.
    • Allergan
    • Pfizer Inc.
    • Tetraphase Pharmaceutical, Inc.
    • TeamHealth
    • Theravance Biopharma
    • WOCKHARDT
    • Entasis Threapeutics
    • Paratek Pharmaceutials, Inc.
    • Seres Therapeutics
    • Achaogen Inc.
    • Basilea Pharmaceutical Ltd.
    • Nabriva Threapeutics plc
    • NEMESIS BIOSCIENCE LTD.

第10章

  • 参考
  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI6668

The global antibiotic resistance market was valued US$ 8.83 Bn in 2023 and is expected to reach US$ 13.37 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.3% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2023/2024: US$ 8.83 Bn
Historical Data for: 2019 to 2023 Forecast Period: 2024 - 2031
Forecast Period 2023/2024 to 2030/2031 CAGR: 5.30% 2030/2031 Value Projection: US$ 13.37 Bn
Figure 1. Global Antibiotic Resistance Market Share (%), By Region, 2023
Global Antibiotic Resistance Market - IMG1

The global antibiotic resistance market has been witnessing significant growth in recent years. Antibiotics are medicines used to prevent and treat bacterial infections. They either kill bacteria or stop them from multiplying. Some of the most commonly used antibiotics include penicillin, amoxicillin, cephalosporins etc. However, over the past few decades, antibiotic resistance has been emerging as a major public health threat globally. When bacteria become antibiotic resistant, the medicines used to treat the infections they cause become ineffective. This leads to longer illness and increased death rates. The rising prevalence of bacterial strains that are resistant to various antibiotic classes is primarily attributable to misuse and overuse of antibiotics. Other factors that drive antibiotic resistance include the lack of development of new antibiotics, lack of sanitation and hygiene in many parts of the world, increased international travels, etc. If not addressed properly, antibiotic resistance could lead to serious health issues and affect patient outcomes.

Market Dynamics:

The global antibiotic resistance market growth is driven by various factors such as increasing prevalence of antibiotic-resistant bacterial infections, lack of new antibiotic development, misuse and overuse of existing antibiotics, limited infection control in many developing regions, etc. However, the development of alternative treatment options and stringent regulations regarding antibiotic usage could restrain the market growth. The market provides opportunities for companies focusing on the development of novel antibiotics with new mechanisms of action. Key players are also exploring alternative therapeutic approaches like phage therapy, vaccines, monoclonal antibodies etc. to counter antibiotic resistance. Partnerships between industry and academia hold promise to address this looming healthcare crisis.

Key Features of the Study:

  • This report provides an in-depth analysis of the global antibiotic resistance market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year
  • It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global antibiotic resistance market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Melinta Therapeutics, Merck & Co., Inc., Allergan, Pfizer Inc., Tetraphase Pharmaceutical, Inc., Theravance Biopharma, WOCKHARDT, Entasis Threapeutics, Paratek Pharmaceutials, Inc., Seres Therapeutics, Achaogen Inc., Basilea Pharmaceutical Ltd., Nabriva Threapeutics plc, NEMESIS BIOSCIENCE LTD.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global antibiotic resistance market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antibiotic resistance market

Detailed Segmentation:

  • Global Antibiotic Resistance Market, By Drug Class
    • Oxazolidinones
    • Lipoglycopeptides
    • Tetracyclines
    • Cephalosporins
    • Others (Combination therapies, etc.)
  • Global Antibiotic Resistance Market, By Disease
    • cUTI (Complicated Urinary Tract Infections)
    • CDI (Clostridioides difficile Infection)
    • ABSSSI (Acute bacterial skin and skin structure infections)
    • HABP (Hospital-acquired bacterial pneumonia)
    • CABP (Community-acquired pneumonia)
    • cIAI (Complicated intra-abdominal infection)
    • Others (BSI (Bloodstream infection), etc.)
  • Global Antibiotic Resistance Market, By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Antibiotic Resistance Market, By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Top Companies in the Global Antibiotic Resistance Market:
    • Melinta Therapeutics
    • Merck & Co., Inc.
    • Allergan
    • Pfizer Inc.
    • Tetraphase Pharmaceutical, Inc.
    • Theravance Biopharma
    • WOCKHARDT
    • Entasis Threapeutics
    • Paratek Pharmaceutials, Inc.
    • Seres Therapeutics
    • Achaogen Inc.
    • Basilea Pharmaceutical Ltd.
    • Nabriva Threapeutics plc
    • NEMESIS BIOSCIENCE LTD.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Disease
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Rising prevalence of infectious diseases
    • Advancement in antibiotic resistance diagnosis
    • Growing number of R&D activities
  • Key Highlights
  • Guidelines for the Temporary Staffing Agency & the Host Employer
  • Market Trends
  • PEST Analysis
  • Investments and Fundings
  • Mergers, Acquisitions, and Collaborations
  • Key Services Offered
  • Identification of Top Market Players
  • Nurse Staffing Dominance
  • Healthcare Spending by Country

4. Global Antibiotic Resistance Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Antibiotic Resistance Market, By Drug Class, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Oxazolidinones
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Lipoglycopeptides
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Tetracyclines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Cephalosporins
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Others (Combination therapies, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)

6. Global Antibiotic Resistance Market, By Disease, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • cUTI (Complicated Urinary Tract Infections)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • CDI (Clostridioides difficile Infection)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • ABSSSI (Acute bacterial skin and skin structure infections)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • HABP (Hospital-acquired bacterial pneumonia)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • CABP (Community-acquired pneumonia)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • cIAI (Complicated intra-abdominal infection)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Others (BSI (Bloodstream infection), etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)

7. Global Antibiotic Resistance Market, By Distribution Channel, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)

8. Global Antibiotic Resistance Market, By Region, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Region, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, For Region, 2020 - 2031
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Disease, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019-2031, (US$ Bn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Company Profile
    • Melinta Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Merck & Co., Inc.
    • Allergan
    • Pfizer Inc.
    • Tetraphase Pharmaceutical, Inc.
    • TeamHealth
    • Theravance Biopharma
    • WOCKHARDT
    • Entasis Threapeutics
    • Paratek Pharmaceutials, Inc.
    • Seres Therapeutics
    • Achaogen Inc.
    • Basilea Pharmaceutical Ltd.
    • Nabriva Threapeutics plc
    • NEMESIS BIOSCIENCE LTD.
  • Analyst Views

10. Section

  • References
  • Research Methodology
  • About us